ER、PR、C-erbB-2和Ki-67在乳腺癌新辅助化疗前后的表达及意义  

作　　者：曹铭谦[1] 张殿龙[1] 姚永强[1] 方红[1] 谢继平[1] 

机构地区：[1]辽宁省大连大学附属中山医院,辽宁大连116001

出　　处：《中国中医药咨讯》2011年第14期12-13,共2页

摘　　要：目的探讨新辅助化疗（NAC）对乳腺癌组织中雌激素受体（estrogen receptor,ER）、孕激素受体（progesterone receptor，PR）C-erbB-2和Ki-67表达及意义。方法采用免疫组化S-P法检测化疗前后56例乳腺癌组织中ER、PR、C—erbB-2和Ki-67的表达。结果新辅助化疗前后ER、PR和C—erbB-2的表达无明显变化（P〉0．05）新辅助化疗前后Ki-67的表达差异有统计学意义（P〈0．05）结论新辅助化疗能显著降低Ki-67的表达，对ER、PR和C-erbB-2的表达状态无明显影响。新辅助化疗后检测可为后续治疗和判断预后提供指导。Objective To study the expression and significance of ER, PR, C-erbB-2 and Ki-67 before and after neo-adjuvant chemotherapy in patients with breast cancer. Methods The immunohistochemical staining method were used to examine the expression of ER, PR, C-erbB-2 and Ki-67. Results The expression of ER, PR and C-erbB-2 have no significant differences difference after neo-adjuvant chemotherapy as compared with before neo-adjuvant chemotherapy （P〉0.05）. The expression of Ki-67 has significantly differences difference after neo-adjuvant chemotherapy as compared with before neo-adjuvant chemotherapy （P〈0.05）. Conclusion The expression of Ki-67 were decreased after neo-adjuvant chemotherapy. Neo-adjuvant chemotherapy has no significant influence on the expression of ER, PR and C-erbB-2.

关 键 词：乳腺肿瘤 新辅助化疗 ER PR C—erbB-2 KI-67 

分 类 号：R737.9[医药卫生—肿瘤]